Lanadelumab

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Lanadelumab and local guidelines before prescribing.

Kallikrein inhibitor

Mechanism

Plasma kallikrein inhibitor monoclonal antibody.

Uses

Hereditary angioedema prophylaxis.

Dosing

No dose is given in the chapters. See the BNF.

Side effects

Injection-site reactions, hypersensitivity, raised APTT.

Interactions

Few.

Contraindications and cautions

Hypersensitivity

Monitoring

Attack frequency

Pregnancy and breastfeeding

Limited data

Renal and hepatic impairment

No adjustment

Overdose and reversal

Supportive

Special advice

Prophylaxis only, not for acute attacks.

More from the textbook: uses, cautions and other points
Where it is discussed in the book